Trial Profile

A Phase 1a Clinical Trial of PT101 for Autoimmune Disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MK 6194 (Primary)
Indications Autoimmune disorders; Ulcerative colitis
Focus Adverse reactions; First in man
Sponsors Pandion Therapeutics

Most Recent Events

15 Jun 2024 Results(n=110) describing safety, pharmacokinetics (PK), and pharmacodynamics , presented at the 25th Annual Congress of the European League Against Rheumatism
05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism
04 Jan 2021 Status changed from active, no longer recruiting to completed, according to a Pandion Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com